HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Boehringer Ingelheim Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Boehringer Ingelheim Intelligence Report

Generated from 11 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 77%

Evidence

39 items

Sources

13

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Boehringer Ingelheim maintains an active intelligence profile across Metabolic Disorders, Oral Therapy, Oncology, Combination Therapy, Breast Cancer. 11 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 77% across 3 tracked sources. Highest-priority development: IND Application Reporting: IND Safety Reports. Regulatory precedent. Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Boehringer Ingelheim.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    IND Application Reporting: IND Safety Reports

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of Drug

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    Clinical trials for medicines: collection, verification and reporting of safety events

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    Sunscreen: How to Help Protect Your Skin from the Sun

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Ongoing | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — ONTRUZANT (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    Ongoing | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 770 with buyer quality 10 (Enterprise). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • IND Application Reporting: IND Safety Reports

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of Drug

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Clinical trials for medicines: collection, verification and reporting of safety events

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • Sunscreen: How to Help Protect Your Skin from the Sun

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Ongoing | Cancer Accelerated Approvals

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ONTRUZANT (SUPPL)

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Ongoing | Cancer Accelerated Approvals

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    High Confidence · 92%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer

    High Confidence · 92%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Medical Products for Rare Diseases and Conditions

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Drug Trials Snapshots: YARTEMLEA

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Drug Trials Snapshots: PALSONIFY

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Boehringer Ingelheim Study on HER2-Altered Metastatic Breast Cancer Treatment Patterns

    Oncology · Breast Cancer

  • Boehringer Ingelheim's Survodutide Trial for NASH/MASH with Cirrhosis Underway

    Hepatology · NASH/MASH

  • Boehringer Ingelheim's BI 764198 Trial Focuses on Safety and Pharmacokinetics

    Metabolic Disorders · Oral Therapy

  • Boehringer Ingelheim Initiates Dose-Exploration Study of BI 1831169 with Anti-PD1 in Advanced Cancer

    Oncology · Combination Therapy

  • Boehringer Ingelheim's Nerandomilast Trial for Lung Fibrosis in Autoimmune Diseases

    Pulmonology · Lung Fibrosis

  • Boehringer Ingelheim's Nerandomilast Trial for Fibrosing ILD Shows Potential for Disease Progression

    Pulmonology · Fibrosing Interstitial Lung Disease

  • Boehringer Ingelheim Initiates Long-term Study of Nerandomilast in Pulmonary Fibrosis Patients

    Pulmonology · Pulmonary Fibrosis

  • Boehringer Ingelheim Tests Vicadrostat with Empagliflozin in CKD Patients

    Nephrology · Chronic Kidney Disease

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.